SYN Synthetic Biologics Inc.

1.01
+0.05  (5%)
Previous Close 0.96
Open 1.05
Price To book 25.25
Market Cap 129745290
Shares 128,460,683
Volume 3,926,608
Short Ratio 4.89
Av. Daily Volume 1,482,411

SEC filingsSee all SEC filings

  1. D - Notice of Exempt Offering of Securities 171082251
  2. 8-K - Current report 171080040
  3. S-8 - Securities to be offered to employees in employee benefit plans 171077190
  4. 8-K - Current report 171077157
  5. 8-K - Current report 171072848

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Second Phase 2 trial commenced October 2015. 12 week data met endpoints. Phase 2b/3 trial planned for 2017.
SYN-010
Constipation-Predominant Irritable Bowel Syndrome (C-IBS)
Pending. Partner Meda has received the go-ahead from the FDA to conduct a Phase 2 proof of concept trial
Flupirtine
Fibromyalgia
License terminated following lack of efficacy shown February 2016
Trimesta
Relapsing-remitting MS in women
Phase 2b topline data released January 5, 2017. Primary endpoint met. Phase 3 trial to be initiated 1H 2018.
SYN-004
C. difficile Infection

Latest News

  1. Synthetic Biologics (SYN) in Focus: Stock Moves 7.7% Higher
  2. Today's Research Reports on Stocks to Watch: Synthetic Biologics and Microbot Medical
  3. Synthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing
  4. Synthetic Biologics, Inc. Provides Company Overview and Update on Clinical Development in New SNNLive Video Interview with StockNewsNow.com
  5. Synthetic Biologics Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017
  6. Edited Transcript of SYN earnings conference call or presentation 3-Aug-17 12:30pm GMT
  7. Zacks.com featured highlights: Stoneridge, Synthetic Biologics, IRadimed Corporation, Syntel and AXT
  8. 5 Cheap Breakout Stocks Offering Strong Returns
  9. Synthetic Biologics reports 2Q loss
  10. Synthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results
  11. Synthetic Biologics to Report Second Quarter 2017 Operational Highlights and Financial Results on August 3, 2017
  12. Synthetic Biologics Announces Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
  13. Can The Uptrend Continue for Synthetic Biologics (SYN)?
  14. Today's Research Reports on Stocks to Watch: Quantum Corporation and Synthetic Biologics
  15. Blog Coverage: Synthetic Biologics Wins Breakthrough Therapy Designation for its Clostridium Difficile Infection Candidate
  16. Edited Transcript of SYN earnings conference call or presentation 4-May-17 8:30pm GMT
  17. SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Prevention of Clostridium difficile Infection
  18. Synthetic Biologics Reports First Quarter 2017 Operational Highlights and Financial Results
  19. Synthetic Biologics to Report First Quarter 2017 Operational Highlights and Financial Results on May 4, 2017

SEC Filings

  1. D - Notice of Exempt Offering of Securities 171082251
  2. 8-K - Current report 171080040
  3. S-8 - Securities to be offered to employees in employee benefit plans 171077190
  4. 8-K - Current report 171077157
  5. 8-K - Current report 171072848
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 171002786
  7. 8-K - Current report 171002749
  8. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17970115
  9. DEF 14A - Other definitive proxy statements 17970104
  10. PRE 14A - Other preliminary proxy statements 17952725